Member Spotlight: Mighty Therapeutics

Nov 16, 2026

Mighty‘s pioneering science starts from a simple but powerful idea: many diseases — rare genetic conditions and common diseases of aging alike — share a root cause in mitochondrial dysfunction. Rather than working around that dysfunction, Mighty’s therapies are designed to directly target the mitochondria and restore healthy bioenergetics. The company’s first therapy received FDA accelerated approval as the first treatment to improve muscle weakness in adult and pediatric patients weighing at least 30 kg with Barth syndrome and was the first approved therapy to directly target mitochondria. With a pipeline extending into other mitochondrial diseases and dry AMD, Mighty is building a new class of medicines with the potential to change how mitochondrial dysfunction is addressed across a variety of diseases.

MassBio Member Spotlight: Mighty Therapeutics

Location: Needham, Massachusetts

Therapeutic area(s): Rare and age-related diseases driven by mitochondrial dysfunction, including Barth syndrome, dry age-related macular degeneration (dry AMD) and POLG-related mitochondrial disease.

Leadership:

Website: mightytx.com

See all MassBio News